RxDoctor Payments Data

James Ladd, PA

Optometrist · Batesville, ARNPI 1508910167

Payments from drug & device makers

$1,252in general payments, 2019–2025

Across 58 payments — averaging $21.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$449
  • Johnson & Johnson Vision Care, Inc.$403
  • Biotissue Holdings Inc.$98
  • Shire North American Group Inc$87
  • Novartis$62
  • Oyster Point Pharma, Inc.$54
  • plus $98 from 5 others

What the payments were for

  • Speaking & faculty fees$18715%
  • Food & beverage$1,06585%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,252 in reported general payments places this provider in the 70th percentile of 442 optometrist providers in Arkansas.

See all optometrist providers in Arkansas

Medicare billing

Part B allowed, 2024
$103,792
Medicare patients
645
Services billed
1,325

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine40$28,736
XiidraLifitegrast12$11,310
LumiganBimatoprost17$6,426
CombiganBrimonidine Tartrate/Timolol17$4,384
Brimonidine Tartrate15$3,105
Travoprost14$2,458
Latanoprost212$1,808
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol15$1,137
Tobramycin-DexamethasoneTobramycin/Dexamethasone11$519
Prednisolone Acetate15$444
Timolol Maleate23$267
ErythromycinErythromycin Base21$265
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha11$141
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav11$139
Ofloxacin12$112

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$33$39,54674 claims
Bausch & Lomb Americas Inc.Xiidra$17$11,31012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 442 optometrist providers in Arkansas.

Other optometrist in Batesville

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →